A phase 3 trial shows that apremilast, an oral phosphodiesterase 4 inhibitor, improves symptoms, disease severity, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results